Literature DB >> 11560959

Signaling through CD28 and CTLA-4 controls two distinct forms of T cell anergy.

A D Wells1, M C Walsh, J A Bluestone, L A Turka.   

Abstract

Primary T cell proliferative responses to TCR ligation plus CD28 costimulation are surprisingly heterogeneous. Many cells that enter G1 fail to progress further through the cell cycle, and some of these cells subsequently fail to divide upon restimulation, even in the presence of IL-2. Such IL-2-refractory anergy is distinct from the IL-2-reversible anergy induced by TCR occupancy in the absence of CD28 costimulation. Here, we focus on the contributions of cell cycle progression and costimulatory (CD28/CTLA-4) signals in the regulation of anergy. We show that CD28 costimulation is not sufficient for anergy avoidance and that activated T cells must progress through the cell cycle in order to escape anergy. Induction of this "division-arrest" form of anergy requires CTLA-4 signaling during the primary response. Also, cell division per se is not sufficient for anergy avoidance: the few T cells that undergo multiple rounds of cell division during overt CD28 costimulatory blockade do not escape the ultimate induction of clonal anergy. Anergy avoidance by primary T cells is thus a multistep process: in order to participate in a productive immune response, an individual T cell activated through its antigen receptor must receive CD28 costimulation and progress through the cell cycle. Anergy may be induced either through a combination of CTLA-4 signaling and the failure of cell cycle progression, or through a proliferation-independent mechanism in which TCR ligation occurs in the absence of CD28.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11560959      PMCID: PMC200935          DOI: 10.1172/JCI13220

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  51 in total

1.  Helper T cell differentiation is controlled by the cell cycle.

Authors:  J J Bird; D R Brown; A C Mullen; N H Moskowitz; M A Mahowald; J R Sider; T F Gajewski; C R Wang; S L Reiner
Journal:  Immunity       Date:  1998-08       Impact factor: 31.745

2.  CTLA-4 regulates tolerance induction and T cell differentiation in vivo.

Authors:  T L Walunas; J A Bluestone
Journal:  J Immunol       Date:  1998-04-15       Impact factor: 5.422

Review 3.  Individual T cells hold unexpected clues to the nature of anergy and memory.

Authors:  A D Wells; L A Turka
Journal:  Immunol Res       Date:  1998       Impact factor: 2.829

4.  Direct evidence that functionally impaired CD4+ T cells persist in vivo following induction of peripheral tolerance.

Authors:  K A Pape; R Merica; A Mondino; A Khoruts; M K Jenkins
Journal:  J Immunol       Date:  1998-05-15       Impact factor: 5.422

Review 5.  Is CTLA-4 a master switch for peripheral T cell tolerance?

Authors:  J A Bluestone
Journal:  J Immunol       Date:  1997-03-01       Impact factor: 5.422

6.  Induction of peripheral T cell tolerance in vivo requires CTLA-4 engagement.

Authors:  V L Perez; L Van Parijs; A Biuckians; X X Zheng; T B Strom; A K Abbas
Journal:  Immunity       Date:  1997-04       Impact factor: 31.745

7.  Following the fate of individual T cells throughout activation and clonal expansion. Signals from T cell receptor and CD28 differentially regulate the induction and duration of a proliferative response.

Authors:  A D Wells; H Gudmundsdottir; L A Turka
Journal:  J Clin Invest       Date:  1997-12-15       Impact factor: 14.808

Review 8.  Cancer cell cycles.

Authors:  C J Sherr
Journal:  Science       Date:  1996-12-06       Impact factor: 47.728

9.  Cell division regulates the T cell cytokine repertoire, revealing a mechanism underlying immune class regulation.

Authors:  A V Gett; P D Hodgkin
Journal:  Proc Natl Acad Sci U S A       Date:  1998-08-04       Impact factor: 11.205

10.  Class I-restricted cross-presentation of exogenous self-antigens leads to deletion of autoreactive CD8(+) T cells.

Authors:  C Kurts; H Kosaka; F R Carbone; J F Miller; W R Heath
Journal:  J Exp Med       Date:  1997-07-21       Impact factor: 14.307

View more
  42 in total

Review 1.  T-cell anergy: from phenotype to genotype and back.

Authors:  Christine M Seroogy; C Garrison Fathman
Journal:  Immunol Res       Date:  2003       Impact factor: 2.829

2.  Distinct IL-2 receptor signaling pattern in CD4+CD25+ regulatory T cells.

Authors:  Steven J Bensinger; Patrick T Walsh; Jidong Zhang; Martin Carroll; Ramon Parsons; Jeffrey C Rathmell; Craig B Thompson; Matthew A Burchill; Michael A Farrar; Laurence A Turka
Journal:  J Immunol       Date:  2004-05-01       Impact factor: 5.422

3.  Association of single nucleotide polymorphisms in cytotoxic T-lymphocyte antigen 4 and susceptibility to autoimmune type 1 diabetes in Tunisians.

Authors:  Jihen Benmansour; Mouna Stayoussef; Fayza A Al-Jenaidi; Mansoor H Rajab; Chiheb B Rayana; Hichem B Said; Touhami Mahjoub; Wassim Y Almawi
Journal:  Clin Vaccine Immunol       Date:  2010-07-07

Review 4.  Molecular mechanisms for adaptive tolerance and other T cell anergy models.

Authors:  Seeyoung Choi; Ronald H Schwartz
Journal:  Semin Immunol       Date:  2007-04-02       Impact factor: 11.130

Review 5.  Cyclin-dependent kinases: molecular switches controlling anergy and potential therapeutic targets for tolerance.

Authors:  Andrew D Wells
Journal:  Semin Immunol       Date:  2007-03-23       Impact factor: 11.130

6.  CTLA-4 on alloreactive CD4 T cells interacts with recipient CD80/86 to promote tolerance.

Authors:  Josef Kurtz; Forum Raval; Casey Vallot; Jayden Der; Megan Sykes
Journal:  Blood       Date:  2009-01-29       Impact factor: 22.113

Review 7.  Induction and stability of the anergic phenotype in T cells.

Authors:  Rut Valdor; Fernando Macian
Journal:  Semin Immunol       Date:  2013-11-05       Impact factor: 11.130

Review 8.  IDO-expressing regulatory dendritic cells in cancer and chronic infection.

Authors:  Alexey Popov; Joachim L Schultze
Journal:  J Mol Med (Berl)       Date:  2007-09-18       Impact factor: 4.599

Review 9.  The biology of interleukin-2 efficacy in the treatment of patients with renal cell carcinoma.

Authors:  Antonio Romo de Vivar Chavez; Michael E de Vera; Xiaoyan Liang; Michael T Lotze
Journal:  Med Oncol       Date:  2009-01-16       Impact factor: 3.064

10.  Alloreactive CD8 T cell tolerance requires recipient B cells, dendritic cells, and MHC class II.

Authors:  Thomas Fehr; Fabienne Haspot; Joshua Mollov; Meredith Chittenden; Timothy Hogan; Megan Sykes
Journal:  J Immunol       Date:  2008-07-01       Impact factor: 5.422

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.